Jordyn Sava is an editor for Targeted Oncology.
AI Tool Accurately Differentiates MPNs Using Bone Marrow Biopsies
December 28th 2023Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.
Symposium Explores Latest Advances in Cancer Rehabilitation
December 19th 2023In an interview with Targeted Oncology, Yazmin Odia, MD, discussed the 3rd Annual Miami Cancer Institute Oncology Rehabilitation Symposium, including her discussion on incorporating rehabilitation into the course of treatment for patients with brain cancer.
Dostarlimab Plus SOC Chemo Meets Primary End Point in Advanced Endometrial Cancer
December 18th 2023Positive headline results from part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO trial support the potential use of dostarlimab as the backbone for therapies in mismatch repair proficient/microsatellite stable primary advanced or recurrent endometrial cancer.
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.